AnGes, Inc. (TYO:4563)

Japan flag Japan · Delayed Price · Currency is JPY
57.00
-1.00 (-1.72%)
Apr 17, 2026, 3:30 PM JST
Market Cap22.55B +13.0%
Revenue (ttm)874.00M +35.9%
Net Income-5.12B
EPS-14.44
Shares Out395.63M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,558,700
Average Volume1,649,270
Open58.00
Previous Close58.00
Day's Range57.00 - 59.00
52-Week Range54.00 - 120.00
Beta0.71
RSI47.00
Earnings DateMay 8, 2026

About AnGes

AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The company was incorporated in 1999 and is headquartered in Ibaraki, Japan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 56
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4563
Full Company Profile

Financial Performance

In 2025, AnGes's revenue was 874.00 million, an increase of 35.93% compared to the previous year's 643.00 million. Losses were -5.12 billion, -81.79% less than in 2024.

Financial Statements